Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15–16

HOS-114832 · Präparat HOS-094169

15  Inhibition of CYP 3A4 by tipranavir/r HMG CoA reductase inhibitors Atorvastatin 10 mg QD Atorvastatin Cmax ↑ 8.6 fold Co-administration of atorvastatin Atorvastatin AUC ↑ 9.4 fold and Aptivus, co-administered Atorvastatin Cmin ↑ 5.2 fold with low dose ritonavir, is not recommended. Other HMG-CoA Tipranavir ↔ reductase inhibitors should be considered such as pravastatin, Inhibition of CYP 3A4 by fluvastatin or rosuvastatin (See tipranavir/r also section 4.4 and rosuvastatin and pravastatin recommendations). In cases where co-administration is necessary, the dose of 10 mg atorvastatin daily should not be exceeded. It is recommended to start with the lowest dose and careful clinical monitoring is necessary (see section 4.4). Rosuvastatin 10 mg QD Rosuvastatin Cmax ↑ 123% Co-administration of Aptivus, co- Rosuvastatin AUC ↑ 37% administered with low dose Rosuvastatin Cmin ↑ 6% ritonavir, and rosuvastatin should be initiated with the lowest dose Tipranavir ↔ (5 mg/day) of rosuvastatin, titrated to treatment response, and Mechanism unknown. accompanied with careful clinical monitoring for rosuvastatin associated symptoms as described in the label of rosuvastatin. Pravastatin Based on similarities in the Co-administration of Aptivus, co- No interaction study elimination between pravastatin administered with low dose performed and rosuvastatin, TPV/r could ritonavir, and pravastatin should increase the plasma levels of be initiated with the lowest dose pravastatin. (10 mg/day) of pravastatin, titrated to treatment response, and Mechanism unknown. accompanied with careful clinical monitoring for pravastatin associated symptoms as described in the label of pravastatin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) ritonavir (HOS-084521) pravastatin (HOS-086306)